Most recent articles by:

Eric Feinstein

Eric Feinstein is the CEO of Clarapath, a medical robotics company headquartered in Hawthorne, NY, catalyzing change in the way pathology laboratories process biopsies. Eric is an operator and investor in medical devices, healthcare services, and healthcare IT. Formerly, he managed and led investment activity at Northwell Ventures. Eric spent a number of years evaluating new investment opportunities at Ampersand Capital and Landmark Partners, as well as in M&A. Eric serves on a number of start-up and growth boards in the medtech and pharma space, holding a degree in Economics from Trinity College and an MBA from Cornell University
- Advertisement -

The Changing Role of a Histotechnologist

Ask a doctor to describe a typical day’s work and her answer will likely sound significantly different than it would have a...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC
- Advertisement -